Aquatic Capital Management LLC Has $900,000 Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Aquatic Capital Management LLC reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 83.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,824 shares of the company's stock after selling 212,176 shares during the period. Aquatic Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $900,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Diversify Advisory Services LLC lifted its stake in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after purchasing an additional 496 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after acquiring an additional 699 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after acquiring an additional 812 shares in the last quarter. Metis Global Partners LLC grew its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after acquiring an additional 860 shares during the last quarter. Finally, DGS Capital Management LLC increased its holdings in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after purchasing an additional 872 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Up 3.8 %

Shares of NYSE:TEVA traded up $0.60 during midday trading on Friday, reaching $16.22. The company's stock had a trading volume of 11,919,719 shares, compared to its average volume of 9,977,348. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a 50 day moving average price of $15.11 and a two-hundred day moving average price of $17.49. The firm has a market capitalization of $18.39 billion, a price-to-earnings ratio of -11.19, a PEG ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TEVA shares. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.